1. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.

    Annals of Oncology 27(5):806 (2016) PMID 26861603

    Despite the effectiveness of adjuvant endocrine therapy in preventing breast cancer recurrence, breast cancer events continue at a high rate for at least 10 years after completion of therapy. This randomised open label phase III trial recruited postmenopausal women from 29 Australian and New Zea...
  2. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

    Annals of Oncology 26(12):2442 (2015) PMID 26387144 PMCID PMC4658543

    We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy wit...
  3. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

    Annals of Oncology 26(8):1533 (2015) PMID 25939896 PMCID PMC4511219

    The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitti...
  4. Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer.

    Annals of Oncology 25(3):755 (2014) PMID 24458471 PMCID PMC4433528

  5. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.

    Breast Cancer Research and Treatment 143(1):159 (2014) PMID 24305979 PMCID PMC3913479

    There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen. Data on patients randomized into the monotherapy arms of...
  6. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

    Annals of Oncology 24(9):2206 (2013) PMID 23917950 PMCID PMC3755334

    The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refi...
  7. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

    Annals of Oncology 23(11):2843 (2012) PMID 22707751 PMCID PMC3477879

    To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12,409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosi...
  8. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.

    British Journal of Cancer 106(10):1618 (2012) PMID 22531635 PMCID PMC3349183

    In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). One hundred postmenopausal women, randomised to receive 5 years of adj...
  9. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

    Annals of Oncology 22(10):2201 (2011) PMID 21335417 PMCID PMC3179413

    On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which arom...
  10. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

    Annals of Oncology 22(10):2216 (2011) PMID 21325445 PMCID PMC3179412

    The International Breast Cancer Study Group Trial VIII compared long-term efficacy of endocrine therapy (goserelin), chemotherapy [cyclophosphamide, methotrexate and fluorouracil (CMF)], and chemoendocrine therapy (CMF followed by goserelin) for pre/perimenopausal women with lymph-node-negative ...
  11. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.

    Breast Cancer Research and Treatment 129(2):467 (2011) PMID 21445568

    Women starting first-line chemotherapy for advanced breast cancer have differing baseline characteristics and survival times. We sought to develop and validate a pragmatic prognostic nomogram to predict overall survival (OS) by using available clinical and laboratory data. The prognostic model w...
  12. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

    Annals of Oncology 22(9):1981 (2011) PMID 21282282 PMCID PMC3202167

    The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-positive lymph node-negative breast cancer is being reassessed. After stratification by ER status, 1669 postmenopausal patients with operable lymph node-negative breast cancer were randomly assigned to th...
  13. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

    Annals of Oncology 22(8):1736 (2011) PMID 21709140 PMCID PMC3144634

    The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these subtypes may ...
  14. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.

    British Journal of Cancer 102(9):1341 (2010) PMID 20389302 PMCID PMC2865758

    Baseline health-related quality of life (QL) is associated with survival in advanced breast cancer. We sought to identify patients who were less likely to respond to chemotherapy and at greater risk of toxicity on the basis of their QL. We used data from three advanced breast cancer trials in wh...
  15. Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of bias.

    European Journal of Cancer 46(3):541 (2010) PMID 20036117

    Randomised controlled trials (RCTs) provide optimal evidence to assess the benefits of new treatments. However, clinicians routinely rely on cross-trial comparisons to assess competing treatments when head-to-head randomised comparisons are unavailable. We investigate the validity of cross-trial...
  16. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.

    Annals of Oncology 21(2):245 (2010) PMID 19633051 PMCID PMC2813305

    Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. Patients participated in two International Breast Cancer Study Group randomized trials testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or post...
  17. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

    Annals of Oncology 20(9):1489 (2009) PMID 19474112 PMCID PMC2731016

    To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial. We evaluated 4895 patients allocated to 5 years of letrozole or t...
  18. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.

    Annals of Oncology 20(8):1344 (2009) PMID 19468030 PMCID PMC2720817

    The role of adjuvant dose-intensive chemotherapy and its efficacy according to baseline features has not yet been established. Three hundred and forty-four patients were randomized to receive seven courses of standard-dose chemotherapy (SD-CT) or three cycles of dose-intensive epirubicin and cyc...
  19. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

    Annals of Oncology 20(8):1319 (2009) PMID 19535820 PMCID PMC2720818

    The 11(th) St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression ...
  20. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

    Annals of Oncology 19(8):1393 (2008) PMID 18385202 PMCID PMC2733063

    Extracapsular tumor spread (ECS) has been identified as a possible risk factor for breast cancer recurrence, but controversy exists regarding its role in decision making for regional radiotherapy. This study evaluates ECS as a predictor of local, axillary, and supraclavicular recurrence. Interna...